Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 228

1.

Hepatic steatosis in HIV-HCV coinfected patients receiving antiretroviral therapy is associated with HCV-related factors but not antiretrovirals.

Martinez V, Ta TD, Mokhtari Z, Guiguet M, Miailhes P, Valantin MA, Charlotte F, Bertheau P, Molina JM, Katlama C, Caumes E.

BMC Res Notes. 2012 Jul 9;5:180. doi: 10.1186/1756-0500-5-180.

2.

HIV coinfection and antiretroviral therapy enhances liver steatosis in patients with hepatitis C, but only in those infected by HCV genotype other than 3.

Borghi V, Puoti M, Mussini C, Bellelli S, Angeletti C, Sabbatini F, Prati F, Cossarizza A, Esposito R.

Antivir Ther. 2008;13(8):1057-65.

PMID:
19195331
3.

Absence of liver steatosis in HIV-HCV co-infected patients receiving regimens containing tenofovir or abacavir.

Borghi V, Bisi L, Manzini L, Cossarizza A, Mussini C.

Infection. 2013 Apr;41(2):425-9. doi: 10.1007/s15010-012-0378-7. Epub 2012 Dec 9.

PMID:
23225268
4.

Hepatic steatosis in HIV-HCV coinfected patients: analysis of risk factors.

Bani-Sadr F, Carrat F, Bedossa P, Piroth L, Cacoub P, Perronne C, Degott C, Pol S; ANRS HC02 - Ribavic Study team.

AIDS. 2006 Feb 28;20(4):525-31.

PMID:
16470116
5.

Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients.

Tural C, Fuster D, Tor J, Ojanguren I, Sirera G, Ballesteros A, Lasanta JA, Planas R, Rey-Joly C, Clotet B.

J Viral Hepat. 2003 Mar;10(2):118-25.

PMID:
12614468
6.

Antiretroviral therapy and sustained virological response to HCV therapy are associated with slower liver fibrosis progression in HIV-HCV-coinfected patients: study from the ANRS CO 13 HEPAVIH cohort.

Loko MA, Bani-Sadr F, Valantin MA, Lascoux-Combe C, Fontaine H, Bonnard P, Gervais A, Bouchaud O, Garipuy D, Quertainmont Y, Vittecoq D, Tehrani MS, Winnock M, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

Antivir Ther. 2012;17(7):1335-43. doi: 10.3851/IMP2419. Epub 2012 Oct 10.

PMID:
23052829
7.

Hepatic steatosis and steatohepatitis in human immunodeficiency virus/hepatitis C virus-coinfected patients.

Macías J, Berenguer J, Japón MA, Girón-González JA, Rivero A, López-Cortés LF, Moreno A, Márquez M, Iribarren JA, Ortega E, Miralles P, Merchante N, Pineda JA.

Hepatology. 2012 Oct;56(4):1261-70. doi: 10.1002/hep.25791. Epub 2012 Sep 11.

PMID:
22508322
8.

Prospective evaluation of hepatic steatosis in HIV-infected patients with or without hepatitis C virus co-infection.

Li Vecchi V, Soresi M, Giannitrapani L, Di Carlo P, Mazzola G, Colletti P, Terranova A, Vizzini G, Montalto G.

Int J Infect Dis. 2012 May;16(5):e397-402. doi: 10.1016/j.ijid.2012.01.011. Epub 2012 Mar 17.

9.

Short communication: atazanavir-based therapy is associated with higher hepatitis C viral load in HIV type 1-infected subjects with untreated hepatitis C.

Rivero-Juarez A, Mira JA, Santos-Gil I, Lopez-Cortes LF, Girón-Gonzalez JA, Marquez M, Merino D, Tellez F, Caruz A, Pineda JA, Rivero A; Grupo Andaluz Para El Estudio de Las Hepatitis Víricas Hepavir de la Sociedad Andaluza de Enfermedades Infecciosas Saei.

AIDS Res Hum Retroviruses. 2013 Feb;29(2):223-5. doi: 10.1089/AID.2012.0126. Epub 2012 Oct 10.

10.

Hepatic steatosis and antiretroviral drug use among adults coinfected with HIV and hepatitis C virus.

Sulkowski MS, Mehta SH, Torbenson M, Afdhal NH, Mirel L, Moore RD, Thomas DL.

AIDS. 2005 Mar 24;19(6):585-92.

PMID:
15802977
11.

Histological findings and clinical characteristics associated with hepatic steatosis in patients coinfected with HIV and hepatitis C virus.

Marks KM, Petrovic LM, Talal AH, Murray MP, Gulick RM, Glesby MJ.

J Infect Dis. 2005 Dec 1;192(11):1943-9. Epub 2005 Nov 2.

12.

Hepatic steatosis in patients coinfected with human immunodeficiency virus/hepatitis C virus: a meta-analysis of the risk factors.

Machado MV, Oliveira AG, Cortez-Pinto H.

Hepatology. 2010 Jul;52(1):71-8. doi: 10.1002/hep.23619.

PMID:
20578130
13.

Incidence and risk factors for steatosis progression in adults coinfected with HIV and hepatitis C virus.

Woreta TA, Sutcliffe CG, Mehta SH, Brown TT, Higgins Y, Thomas DL, Torbenson MS, Moore RD, Sulkowski MS.

Gastroenterology. 2011 Mar;140(3):809-17. doi: 10.1053/j.gastro.2010.11.052. Epub 2010 Dec 4.

14.

Influence of concomitant antiretroviral therapy on the rate of sustained virological response to pegylated interferon plus ribavirin in hepatitis C virus/HIV-coinfected patients.

Pineda JA, Mira JA, Gil Ide L, Valera-Bestard B, Rivero A, Merino D, Girón-González JA, Ríos-Villegas MJ, González-Serrano M, Collado A, García-García JA, Carrillo-Gómez R, López-Cortés LF, Gómez-Mateos J.

J Antimicrob Chemother. 2007 Dec;60(6):1347-54. Epub 2007 Oct 14.

15.

Hepatotoxicity and effectiveness of a Nevirapine-based antiretroviral therapy in HIV-infected patients with or without viral hepatitis B or C infection in Cameroon.

Mbougua JB, Laurent C, Kouanfack C, Bourgeois A, Ciaffi L, Calmy A, Gwet H, Koulla-Shiro S, Ducos J, Mpoudi-Ngolé E, Molinari N, Delaporte E.

BMC Public Health. 2010 Mar 1;10:105. doi: 10.1186/1471-2458-10-105.

16.

Correlates of HIV sustained viral suppression in HIV/hepatitis C virus coinfected patients: possible role of the hepatitis C virus sustained viral response.

Bani-Sadr F, Loko MA, Pambrun E, Winnock M, Carrieri P, Gilbert C, Duvivier C, Bouchaud O, Gervais A, Dabis F, Salmon D; ANRS CO 13 HEPAVIH Study Group.

AIDS. 2014 May 15;28(8):1155-60. doi: 10.1097/QAD.0000000000000218.

PMID:
24499953
17.

Positive impact of hepatitis C virus (HCV) treatment on antiretroviral treatment adherence in human immunodeficiency virus-HCV coinfected patients: one more argument for expanded access to HCV treatment for injecting drug users.

Roux P, Fugon L, Winnock M, Salmon-Céron D, Lacombe K, Sogni P, Spire B, Dabis F, Carrieri MP; ANRS-CO-13-HEPAVIH Study Group.

Addiction. 2012 Jan;107(1):152-9. doi: 10.1111/j.1360-0443.2011.03608.x. Epub 2011 Oct 12.

PMID:
21819472
18.

Acute hepatitis C in persons infected with the human immunodeficiency virus (HIV): the "real-life setting" proves the concept.

Obermeier M, Ingiliz P, Weitner L, Cordes C, Moll A, Hintsche B, Schlote F, Koeppe S, Christensen S, Mayr C, Baumgarten A.

Eur J Med Res. 2011 May 12;16(5):237-42.

19.

Influence of liver fibrosis on highly active antiretroviral therapy-associated hepatotoxicity in patients with HIV and hepatitis C virus coinfection.

Aranzabal L, Casado JL, Moya J, Quereda C, Diz S, Moreno A, Moreno L, Antela A, Perez-Elias MJ, Dronda F, Marín A, Hernandez-Ranz F, Moreno A, Moreno S.

Clin Infect Dis. 2005 Feb 15;40(4):588-93. Epub 2005 Jan 21.

20.

Impact of highly active antiretroviral therapy on the spectrum of liver disease in HCV-HIV coinfection.

Sterling RK, Wilson MS, Sanyal AJ, Luketic VA, Stravitz RT, Contos MJ, Mills AS, Shiffman ML.

Clin Gastroenterol Hepatol. 2004 May;2(5):432-9.

PMID:
15118983
Items per page

Supplemental Content

Write to the Help Desk